Our free guide compiles a range of experimental protocols to help guide researchers through the processes of culturing and seeding different types of organoids.
Researchers at McGill University in Montreal, Quebec investigated the role of Doublecortin (DCX) in regulating neuronal branching through its influence on tubulin polyglutamylation.
Retinitis pigmentosa (RP) and retinal dystrophy are debilitating genetic disorders that lead to progressive vision loss due to the degeneration of photoreceptor cells in the retina. Despite advances in genetic research, effective treatments remain limited, making the development of innovative research models crucial. Organoids and Mesh MEA (microelectrode array, also referred to as multielectrode array) technology from Multi Channel Systems have emerged as powerful tools in studying these diseases, providing insights into retinal function and potential therapeutic approaches.
DSI's SoHo Implantable Telemetry platform revolutionizes small animal research by enabling comprehensive biopotential monitoring. Capture EEG, EMG, ECG, body temperature, and locomotor activity with minimal invasiveness. Designed for extra-small to medium animal models, this system enhances research precision, reduces experimental stress, and provides unprecedented insights across neuroscience, cardiovascular, and behavioral studies.
Organoid electrophysiology is providing pharmaceutical and biotech companies with human-relevant models for testing drug efficacy, modeling diseases, and reducing reliance on animal studies, ultimately accelerating the development of safer and more effective therapeutics.
The integration of behavioral telemetry and organoid research is transforming neuroscience and biomedical science by linking cellular models with complex biological behaviors.
Need a pump? We'll help you choose. Download our free Pump Selection Guide to help you choose the right pump for your application and budget.
According to a recent study published by The Lancet Neurology with contributions from the World Health Organization (WHO), neurological conditions such as, dementia, epilepsy, stroke, and migraine affect more than three billion people worldwide, making these conditions the leading cause of illness and disability globally. Despite advances in neuroscience research, many of these conditions do not have fully effective treatments, making the development of innovative therapies a pressing need.
Harvard Bioscience is gearing up to showcase its latest innovations at the Society for Neuroscience (SfN) 2024 meeting, happening from October 5-9 in Chicago, IL.
